The Coca-Cola Company is a global leader in the beverage industry, renowned for its portfolio of soft drinks, juices, teas, coffees, and water products. Headquartered in Atlanta, Georgia, the company focuses on manufacturing, marketing, and distributing non-alcoholic beverages, with its flagship product being the iconic Coca-Cola soft drink. With a commitment to sustainability and innovation, Coca-Cola continually expands its offerings to meet consumer preferences, emphasizing healthier options and environmentally friendly practices. The company operates in numerous markets worldwide, leveraging its extensive distribution network to ensure that its products are accessible to a diverse range of consumers. Read More
Tesla is facing a federal class action lawsuit accusing it of favoring H-1B visa holders over U.S. workers to cut labor costs, even as the company battles financial headwinds and regulatory scrutiny.
The global financial landscape is currently grappling with a potent concoction of heightened market instability, pervasive policy uncertainty, and an escalating array of geopolitical events. These formidable forces are collectively reshaping investment strategies and underscoring the critical need for robust diversification and strategic hedging within portfolios. As investors navigate these
Shares of luxury furniture retailer RH (NYSE:RH) fell 4.6% in the afternoon session after the company reported disappointing second-quarter results and provided a weak outlook for the upcoming quarter.
Shares of online study and academic help platform Chegg (NYSE:CHGG) fell 4.9% in the afternoon session after continued concerns about the competitive threat posed by Artificial Intelligence (AI).
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v. Natera Inc.,' was reported by the Daily Journal. While the financial impact of the settlement may not be substantial for a company of Natera's scale, news of legal disputes can create uncertainty among investors. The announcement may have raised concerns regarding the underlying issues of the lawsuit or the potential for future legal challenges, prompting a sell-off in the company's shares.
Shares of fast-food chain Wingstop (NASDAQ:WING)
fell 3.7% in the afternoon session after investor sentiment soured amid reports of rising short interest and significant insider selling.
Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.2% in the afternoon session after reports emerged of increased competition from a Chinese rival and news of a significant legal settlement.
As the prospect of a new Trump administration looms, financial markets find themselves in a complex dance, balancing the exhilarating promise of renewed business-friendly policies against the ominous shadow of potential trade wars and inflation. Investors are grappling with a stark dichotomy: the lure of deeper corporate tax cuts and
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN)
fell 3.5% in the afternoon session after Jefferies lowered its price target on the stock.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
fell 2.4% in the afternoon session after the stock extended its negative momentum as Piper Sandler initiated coverage of the stock with a Neutral rating and a $15.00 price target.
Shares of gaming, betting and entertainment company Bally's Corporation (NYSE:BALY)
fell 0.9% in the morning session after the company announced amendments to its credit facility and secured lender consent for the sale and leaseback of its Twin River Lincoln Casino Resort.
Shares of technology real estate company Opendoor (NASDAQ:OPEN)
fell 9.7% in the morning session after it pulled back from a recent massive rally that was reportedly driven by investor activity on social media rather than fundamental business news. The stock waa on a volatile run, surging 142% in August and climbing another 36% in early September. According to reports, this significant price increase was not connected to meaningful progress in the business but was instead the result of activist and retail investors coordinating online.
Shares of application security provider F5 (NASDAQ:FFIV) jumped 2.3% in the afternoon session after the company announced its intent to acquire enterprise AI security firm CalypsoAI for $180 million.
Shares of digital infrastructure investor DigitalBridge Group (NYSE:DBRG) jumped 8.1% in the afternoon session after its portfolio company, Vantage Data Centers, secured a $1.6 billion investment to expand its operations in the Asia-Pacific region.
Shares of regional banking company Origin Bancorp (NYSE:OBK) fell 6.1% in the afternoon session after it disclosed that a customer, Tricolor Holdings, filed for Chapter 7 bankruptcy, prompting the bank to place approximately $30.1 million in loans on non-accrual status.
LOS ANGELES, Calif., Sept. 11, 2025 (SEND2PRESS NEWSWIRE) -- A forgotten genius of mid-century advertising is finally getting his due. The newly launched Paul Stanley Museum, opening in Los Angeles in 2026, will honor the legacy of Paul Stanley Company - the creative powerhouse behind some of America's most beloved animated beer and soda advertising signs.
Shares of technology real estate company Opendoor (NASDAQ:OPEN)
jumped 55% in the morning session after the company announced a significant management shake-up, including a new chief executive and the return of its co-founders to the board.
Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 4.4% in the morning session after the company announced it settled litigation with generic drug manufacturers to extend patent protection for its blockbuster autoimmune drug, RINVOQ. The agreement prevents generic competition for the drug in the U.S. until at least April 2037, a significant victory for the company. This extension provides about five more years of market exclusivity than some analysts had previously expected. RINVOQ is a crucial growth driver for AbbVie, especially as it manages lost revenue from its former mega-blockbuster, Humira. The drug's sales have been climbing rapidly, reaching $6 billion the previous year and are forecast to potentially hit peak sales of over $12 billion. This settlement secures a major future revenue stream for the company.
